ArticleScientific reports2025
Synthesis, antiproliferative screening, and molecular docking of some heterocycles derived from N-(1-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-hydrazineyl-3-oxoprop-1-en-2-yl)benzamide.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hydrazide derivative synthesized from oxazolone was employed as a key building block for the preparation of various N-acetyl, N-benzoyl, imidazole, tetrazine, pyrazole, and pyrazolopyrazole compounds. These target heterocycles were obtained by reacting the hydrazide with several carbon-based electrophilic reagents, including chloroacetyl chloride, benzoyl chloride, acetic anhydride, carbon disulfide, and pyrazole aldehyde. The synthesized compounds were evaluated for their antiproliferative activity against colon (HCT-116) and breast (MCF-7) cancer cell lines, which implied the more selective toxicity of these derivatives toward cancer cell lines rather than normal cell line (WI-38), signifying the safety of the tested compounds. Biological screening results demonstrated that compounds 5, 8, 9, and 10 exhibited significant cytotoxic activity against both cell lines. Among molecular docking simulation, the ligand binding energies were like those of doxorubicin (as an anticancer drug) and RRC (as a CDK2 inhibitor), as the most interacting amino acids were common, proposing being CDK2 inhibitor. The superlative docking score was given by compound 9 (S= -9.5080 kcal/mol), which was higher than that of doxorubicin and co-crystallized ligand (RRC). This work may develop the innovative, highly effective agents against cancer in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.